Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Boston Scientific Falls as Revenue Outlook Disappoints

Published 02/02/2022, 10:41 AM
Updated 02/02/2022, 10:42 AM
© Reuters.

© Reuters.

By Dhirendra Tripathi

Investing.com – Boston Scientific stock (NYSE:BSX) traded 5.5% lower Wednesday after the medical devices maker projected an outlook that traders think was weak considering its 2021 revenue growth of 20%.

The company is now guiding for full-year net sales to grow 6%-8%, less than half of the growth in the year gone by when sales hit nearly $12 billion.    

It expects adjusted profit per share to be $1.76 at the center of its guidance range for the year.

The maker of coronary stents and defibrillators recorded the highest revenue growth in its cardiovascular business. The segment grew more than 25% to $1.3 billion in revenue. Other businesses grew less than half of that pace though all grew in double digits at segment level.

Growth in emerging markets and U.S. were strongest as restrictions were lowered and people attended to health issues they were forced to ignore during the pandemic.

Fourth-quarter net sales rose more than 15% to exceed $3.1 billion. Adjusted EPS came in at 45 cents and beat estimates.

For the current quarter, the company expects net sales to rise 5%-8% while adjusted EPS is seen at 39 cents at the midpoint of its guidance range.  

 

  

 

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.